Lansen Pharmaceutical Holdings Limited provided earnings guidance for the year ended December 31, 2021. For the year ended December 31, 2021, the group's revenue is expected to be about the same as last year; the group's operating profit is expected to record a significant decrease of approximately 38% as compared with that of last year; and the group's net profit is expected to record a significant decrease of approximately 99% as compared with that of last year.
Lansen Pharmaceutical Holdings Limited
Equities
503
KYG5380M1033
Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |